Welcome to our dedicated page for MILESTONE SCIENTIFIC SEC filings (Ticker: MLSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MILESTONE SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MILESTONE SCIENTIFIC's regulatory disclosures and financial reporting.
Form 144 notice filed regarding proposed sale of 400,000 shares of Milestone Scientific, Inc. common stock, with an aggregate market value of $236,000, scheduled approximately for 09/10/2025 on the NYSE. The filing lists 78,559,147 shares outstanding for the class. The securities to be sold were originally acquired in a private placement on 05/14/2014 (2,000,000 shares) from Milestone Scientific, paid in cash. The form also reports a recent sale by BP4 Srl of 375,485 shares on 06/02/2025 for $301,082. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Milestone Scientific (NYSE:MLSS) filed a routine Form 4 reporting two small open-market sales by 10 % owner BP4 S.r.l. The insider sold 10,056 shares on 06/16/2025 at $0.8951 and 1,693 shares on 06/18/2025 at $0.88, totaling 11,749 shares (≈ $10.5 K).
Following the transactions, BP4 S.r.l.’s beneficial ownership declined by less than 0.2 % to 9,447,183 common shares. No derivative trades or additional material changes were disclosed.